Evogliptin (BioDeep_00000015392)
代谢物信息卡片
Evogliptin
化学式: C19H26F3N3O3 (401.1926)
中文名称:
谱图信息:
最多检出来源 not specific(not specific) 0%
分子结构信息
SMILES: CC(C)(C)OCC1C(=O)NCCN1C(=O)CC(CC2=CC(=C(C=C2F)F)F)N
InChI: InChI=1S/C19H26F3N3O3/c1-19(2,3)28-10-16-18(27)24-4-5-25(16)17(26)8-12(23)6-11-7-14(21)15(22)9-13(11)20/h7,9,12,16H,4-6,8,10,23H2,1-3H3,(H,24,27)/t12-,16-/m1/s1
描述信息
A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BH - Dipeptidyl peptidase 4 (dpp-4) inhibitors
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98086 - Dipeptidyl Peptidase-4 Inhibitor
C471 - Enzyme Inhibitor > C783 - Protease Inhibitor
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- KEGG: C92448
- KEGGdrug: D11023
- PubChem: 25022354
- DrugBank: DB12625
- ChEMBL: CHEMBL1779710
- CAS: 1222102-29-5
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Trong Kha Pham, To Hoai T Nguyen, Joo Mi Yi, Gwang Sil Kim, Hyeong Rok Yun, Hyoung Kyu Kim, Jong Chul Won. Evogliptin, a DPP-4 inhibitor, prevents diabetic cardiomyopathy by alleviating cardiac lipotoxicity in db/db mice.
Experimental & molecular medicine.
2023 Apr; ?(?):. doi:
10.1038/s12276-023-00958-6. [PMID: 37009790] - Seong-Joon Lee, Bok Seon Yoon, Ji Man Hong, Eun-Hye Joe, Jin Soo Lee. Effects of co-administration of metformin and evogliptin on cerebral infarct volume in the diabetic rat.
Experimental neurology.
2022 02; 348(?):113922. doi:
10.1016/j.expneurol.2021.113922. [PMID: 34780772] - Qizhi Tang, Weiyu Pan, Liangyue Peng. The efficacy and safety of evogliptin for type 2 diabetes mellitus: A systematic review and meta-analysis.
Frontiers in endocrinology.
2022; 13(?):962385. doi:
10.3389/fendo.2022.962385. [PMID: 36060938] - Hojin Oh, Hai Duc Nguyen, In Mo Yoon, Min-Sun Kim. Efficacy and Tolerability of Evogliptin in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis with Bayesian Inference Through a Quality-management System.
Clinical therapeutics.
2021 08; 43(8):1336-1355. doi:
10.1016/j.clinthera.2021.06.001. [PMID: 34304912] - Hyunyee Yoon, Su Hee Cho, Yu Rim Seo, Kyung-Sang Yu, Sung Sup Park, Moon Jung Song. Optimization and validation of a fluorogenic dipeptidyl peptidase 4 enzymatic assay in human plasma.
Analytical biochemistry.
2021 01; 612(?):113952. doi:
10.1016/j.ab.2020.113952. [PMID: 32926865] - Jin Hyun Kim, Si Jung Jang, Gu Seob Roh, Hyun Seop Cho, Heeyoung Kang, Soo Kyoung Kim. Protective Effects of Evogliptin on Steatohepatitis in High-Fat-Fed Mice.
International journal of molecular sciences.
2020 Sep; 21(18):. doi:
10.3390/ijms21186743. [PMID: 32937958] - Mi Jin Kim, Na Young Kim, Yun A Jung, Seunghyeong Lee, Gwon Soo Jung, Jung Guk Kim, In Kyu Lee, Sungwoo Lee, Yeon Kyung Choi, Keun Gyu Park. Evogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice.
Diabetes & metabolism journal.
2020 02; 44(1):186-192. doi:
10.4093/dmj.2018.0271. [PMID: 31701692] - Inyoung Hwang, Yun Kim, Hyounggyoon Yoo, In-Jin Jang, Kyung-Sang Yu, SeungHwan Lee. Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects.
Drug design, development and therapy.
2020; 14(?):4493-4502. doi:
10.2147/dddt.s275336. [PMID: 33122892] - Hyounggyoon Yoo, Yun Kim, In-Jin Jang, Kyung-Sang Yu, SeungHwan Lee. Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects.
Drug design, development and therapy.
2020; 14(?):5179-5187. doi:
10.2147/dddt.s275343. [PMID: 33262578] - Phuc Anh Nguyen, Jong Soon Won, Md Khalilur Rahman, Eun Ju Bae, Min Kyung Cho. Modulation of Sirt1/NF-κB interaction of evogliptin is attributed to inhibition of vascular inflammatory response leading to attenuation of atherosclerotic plaque formation.
Biochemical pharmacology.
2019 10; 168(?):452-464. doi:
10.1016/j.bcp.2019.08.008. [PMID: 31421133] - Tae-Hyoung Kim, Jeong-Ha Lee, Yu Na Chae, Il-Hoon Jung, Mi-Kyung Kim. Additive effects of evogliptin in combination with pioglitazone on fasting glucose control through direct and indirect hepatic effects in diabetic mice.
European journal of pharmacology.
2018 Jul; 830(?):95-104. doi:
10.1016/j.ejphar.2018.04.033. [PMID: 29727638] - Dae Young Lee, Ju-Hyun Kim, Hyun Joo Shim, Hyeon-Uk Jeong, Hye Suk Lee. Absorption, metabolism, and excretion of [14C]evogliptin tartrate in male rats and dogs.
Journal of toxicology and environmental health. Part A.
2018; 81(11):453-464. doi:
10.1080/15287394.2018.1451194. [PMID: 29557727] - E S Oh, C Choi, C O Kim, K H Kim, Y N Kim, S J Kim, M S Park. Effects of clarithromycin on the pharmacokinetics of evogliptin in healthy volunteers.
Journal of clinical pharmacy and therapeutics.
2017 Dec; 42(6):689-694. doi:
10.1111/jcpt.12604. [PMID: 28806472] - Dae Y Lee, Hye W Chae, Hyun J Shim. In vitro evaluation of potential transporter-mediated drug interactions of evogliptin.
Biopharmaceutics & drug disposition.
2017 Sep; 38(6):398-403. doi:
10.1002/bdd.2083. [PMID: 28503751] - Mi-Kyung Kim, Yu Na Chae, Gook-Jun Ahn, Chang Yell Shin, Song-Hyen Choi, Eun Kyoung Yang, Yong Sung Sohn, Moon-Ho Son. Prevention and treatment effect of evogliptin on hepatic steatosis in high-fat-fed animal models.
Archives of pharmacal research.
2017 Feb; 40(2):268-281. doi:
10.1007/s12272-016-0864-z. [PMID: 27885461] - Jaeseong Oh, Andrew HyoungJin Kim, SeungHwan Lee, Hyunjeong Cho, Yon Su Kim, Mi Young Bahng, Seo Hyun Yoon, Joo-Youn Cho, In-Jin Jang, Kyung-Sang Yu. Effects of renal impairment on the pharmacokinetics and pharmacodynamics of a novel dipeptidyl peptidase-4 inhibitor, evogliptin (DA-1229).
Diabetes, obesity & metabolism.
2017 02; 19(2):294-298. doi:
10.1111/dom.12813. [PMID: 27761990] - Xueying Tan, Jingbo Hu. Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes.
Expert opinion on pharmacotherapy.
2016 Jun; 17(9):1285-93. doi:
10.1080/14656566.2016.1183645. [PMID: 27156529] - Jee Eun Lee, Jung Eun Kim, Mi Hwa Lee, Hye Kyoung Song, Jung Yeon Ghee, Young Sun Kang, Hye Sook Min, Hyun Wook Kim, Jin Joo Cha, Jee Young Han, Sang Youb Han, Dae Ryong Cha. DA-1229, a dipeptidyl peptidase IV inhibitor, protects against renal injury by preventing podocyte damage in an animal model of progressive renal injury.
Laboratory investigation; a journal of technical methods and pathology.
2016 05; 96(5):547-60. doi:
10.1038/labinvest.2016.34. [PMID: 26878135] - Tae-Hyoung Kim, Mi-Kyung Kim, Ye-Hwang Cheong, Yu-Na Chae, Youngyi Lee, Sun-O Ka, Il-Hoon Jung, Chang-Yell Shin, Eun Ju Bae, Moon-Ho Son. Hepatic role in an early glucose-lowering effect by a novel dipeptidyl peptidase 4 inhibitor, evogliptin, in a rodent model of type 2 diabetes.
European journal of pharmacology.
2016 Jan; 771(?):65-76. doi:
10.1016/j.ejphar.2015.11.029. [PMID: 26621343] - Chang Hee Jung, Cheol-Young Park, Kyu-Joeng Ahn, Nan-Hee Kim, Hak-Chul Jang, Moon-Kyu Lee, Joong-Yeol Park, Choon-Hee Chung, Kyung-Wan Min, Yeon-Ah Sung, Jeong-Hyun Park, Sung Jin Kim, Hyo Jung Lee, Sung-Woo Park. A randomized, double-blind, placebo-controlled, phase II clinical trial to investigate the efficacy and safety of oral DA-1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise.
Diabetes/metabolism research and reviews.
2015 Mar; 31(3):295-306. doi:
10.1002/dmrr.2613. [PMID: 25362864] - Yu-Na Chae, Tae-Hyoung Kim, Mi-Kyung Kim, Chang-Yell Shin, Il-Hoon Jung, Yong Sung Sohn, Moon-Ho Son. Beneficial Effects of Evogliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, on Adiposity with Increased Ppargc1a in White Adipose Tissue in Obese Mice.
PloS one.
2015; 10(12):e0144064. doi:
10.1371/journal.pone.0144064. [PMID: 26633898] - Namyi Gu, Min Kyu Park, Tae-Eun Kim, Mi Young Bahng, Kyoung Soo Lim, Sang-Heon Cho, Seo Hyun Yoon, Joo-Youn Cho, In-Jin Jang, Kyung-Sang Yu. Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers.
Drug design, development and therapy.
2014; 8(?):1709-21. doi:
10.2147/dddt.s65678. [PMID: 25336915] - Mi-Kyung Kim, Yu Na Chae, Ha Dong Kim, Eun Kyoung Yang, Eun Jung Cho, Song-hyen Choi, Ye-Hwang Cheong, Hae-Sun Kim, Heung Jae Kim, Yeong Woo Jo, Moon-Ho Son, Soon-Hoe Kim, Chang Yell Shin. DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes.
Life sciences.
2012 Jan; 90(1-2):21-9. doi:
10.1016/j.lfs.2011.10.007. [PMID: 22056373] - Jae Min Cho, Hye Won Jang, Hwanju Cheon, Yeon Taek Jeong, Do-Hoon Kim, Yu-Mi Lim, Song-Hyen Choi, Eun-Kyoung Yang, Chang-Yell Shin, Moon Ho Son, Soon Hoe Kim, Heung-Jae Kim, Myung-Shik Lee. A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis.
Diabetes research and clinical practice.
2011 Jan; 91(1):72-9. doi:
10.1016/j.diabres.2010.10.012. [PMID: 21093089]
